Stable Peptide Akt Capture Agents for Accurate Biomarker Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker assays for diseases like cancer face challenges in producing stable antibodies for complex targets, necessitating the development of stable, synthetic capture agents that can reproducibly and effectively detect and inhibit Akt for diagnostic and therapeutic purposes.
Innovation Solution
Development of stable, synthetic Akt capture agents comprising triligands with specific peptide sequences and a 1,4-substituted-1,2,3-triazole residue linkage, which are stable across various temperatures, pH levels, and storage conditions, and can function as allosteric inhibitors of Akt activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibodies are used for biomarker detection, then high affinity and selectivity can be achieved, but stability and reproducibility are compromised
Solution Approach 1:
The patent creates synthetic peptide mimics that copy the binding functionality of antibodies against Akt, replacing the biological molecule (antibody) with a chemically synthesized analogue that maintains affinity and selectivity while improving stability. The peptides are designed to replicate the epitope recognition capability without the instability inherent in protein-based antibodies.
Solution Approach 2:
The patent modifies the chemical structure of the capture agent by incorporating non-natural amino acids and specific peptide sequences (such as those containing azido groups and triazole linkages) to enhance stability. The synthesis conditions and molecular structure are optimized to create a chemically stable molecule that resists degradation while maintaining biological activity.
2Reliability
If synthetic capture agents are developed to replace antibodies, then stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent divides the capture agent into modular components: an anchor peptide segment that binds to the target protein, and a functional segment containing the azido group and triazole linkage that provides stability and detectability. This segmentation allows each component to be optimized independently and simplifies the overall synthesis process compared to creating entirely new molecular structures.
Solution Approach 2:
The patent uses a triazole linkage as an intermediary chemical structure that connects the anchor peptide to the functional groups. This intermediary element facilitates the synthesis process by providing a stable, well-defined chemical connection that can be formed through reliable coupling reactions, reducing the complexity of assembling the complete capture agent.
3Reliability
If capture agents must remain stable under varying conditions, then reliability is improved, but functional activity may be reduced
Solution Approach 1:
The patent applies different chemical properties to different parts of the capture agent: the anchor peptide region is designed for high-affinity binding to Akt, while the functional region with the triazole linkage and azido group is optimized for stability. Each region has localized structural and chemical characteristics that fulfill its specific function without compromising the other.
Solution Approach 2:
The capture agent is a composite molecular structure combining natural peptide bonds with synthetic chemical linkages (triazole, azido groups). This composite design integrates the binding capabilities of natural proteins with the chemical stability of synthetic molecules, achieving both high affinity and long-term stability simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The capture agents provide stable detection and inhibition of Akt, enabling accurate diagnosis and treatment of cancer by maintaining stability and effectiveness in biological samples, including immunoassays and therapeutic applications.
Implementation Method 1
the linkage between one or more of the anchor ligand, secondary ligand, and tertiary ligand comprises a 1,4-substituted-1,2,3-triazole residue (Tz4)
Data Source
AI summary
The present application provides stable peptide-based Akt capture agents and the use thereof as detection, diagnosis, and treatment agents. The application further provides novel methods of developing stable peptide-based capture agents, including Akt capture agents, using iterative on-bead in situ click chemistry.